$ImmunoPrecise Antibodies (IPA.US)$
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutics company, has received a notification from Nasdaqregarding non-compliance with the minimum bid price requirement. The notification, received on August 19, 2024, states that IPA's common shares closed below $1.00 for 30 consecutive business days from July 5 to August 15, 2024, violating Nasdaq Rule 5450(a)(1). T...
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutics company, has received a notification from Nasdaqregarding non-compliance with the minimum bid price requirement. The notification, received on August 19, 2024, states that IPA's common shares closed below $1.00 for 30 consecutive business days from July 5 to August 15, 2024, violating Nasdaq Rule 5450(a)(1). T...
1
$Quantum BioPharma (QNTM.US)$
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
Quantum BioPharma (NASDAQ:QNTM) has announced several corporate updates. Effective August 30, 2024, Donal Carroll will become CFO, Nathan Coyle will be Controller, and Jason Sawyer will be Head of Finance and M&A. The company has cancelled 32,690 options with exercise prices ranging from $84.50 to $189.15 per Class B Share. Additionally, 32,690 RSUs were grantedto cer...
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
Quantum BioPharma (NASDAQ:QNTM) has announced several corporate updates. Effective August 30, 2024, Donal Carroll will become CFO, Nathan Coyle will be Controller, and Jason Sawyer will be Head of Finance and M&A. The company has cancelled 32,690 options with exercise prices ranging from $84.50 to $189.15 per Class B Share. Additionally, 32,690 RSUs were grantedto cer...
2
$Syros Pharmaceuticals (SYRS.US)$
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemi...
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemi...
$MIRA Pharmaceuticals (MIRA.US)$
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
$MEDIROM Healthcare Technologies (MRM.US)$
Medirom Healthcare Technologies- Capital and Business Alliance Formed Between Medirom Mother Labs and Nfes Technologies
Medirom Healthcare Technologies- Nfes Group to Be Lead Investor in Mother Labs’ Series a Financing Round Valuing It at 9 Bln Yen on Pre-Money Basis
Medirom Healthcare Technologies- Capital and Business Alliance Formed Between Medirom Mother Labs and Nfes Technologies
Medirom Healthcare Technologies- Nfes Group to Be Lead Investor in Mother Labs’ Series a Financing Round Valuing It at 9 Bln Yen on Pre-Money Basis
1
$Draganfly (DPRO.US)$
Draganfly Announces Effective Date of Share Consolidation
Draganfly Inc. (NASDAQ: DPRO) has announced a 1-for-25 share consolidation effective September 3, 2024. This move aims to ensure compliance with Nasdaq listing requirements. Post-consolidation, the company's outstanding common shares will reduce from 87,166,435 to 3,486,658. The consolidation will adjust the exercise price and number of shares issuable under outstanding convertible securities proportionately. Shar...
Draganfly Announces Effective Date of Share Consolidation
Draganfly Inc. (NASDAQ: DPRO) has announced a 1-for-25 share consolidation effective September 3, 2024. This move aims to ensure compliance with Nasdaq listing requirements. Post-consolidation, the company's outstanding common shares will reduce from 87,166,435 to 3,486,658. The consolidation will adjust the exercise price and number of shares issuable under outstanding convertible securities proportionately. Shar...
$Virax Biolabs (VRAX.US)$
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares